nature portfolio

Corresponding author(s): Arutha Kulasinghe

Last updated by author(s): Oct 18, 2025

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a	Confirmed	
☐	☒	The exact sample size (*n*) for each experimental group/condition, given as a discrete number and unit of measurement
☐	☒	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
☐	☒	The statistical test(s) used AND whether they are one- or two-sided *Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
☐	☒	A description of all covariates tested
☐	☒	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
☐	☒	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
☐	☒	For null hypothesis testing, the test statistic (e.g. *F*, *t*, *r*) with confidence intervals, effect sizes, degrees of freedom and *P* value noted *Give P values as exact values whenever suitable.*
☒	☐	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
☒	☐	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
☒	☐	Estimates of effect sizes (e.g. Cohen's *d*, Pearson's *r*), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection	Computer code was not used for data collection.
Data analysis	Code for this study is available at https://github.com/clinicalomx/Adjuvant_Spatial_Multiomic_Profiling

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Data from this study, including the spatial proteomics data, spatial transcriptomics data and metadata are available at https://doi.org/10.48610/3244c1b

Research involving human participants, their data, or biological material

Policy information about studies with human participants or human data. See also policy information about sex, gender (identity/presentation), and sexual orientation and race, ethnicity and racism.

Reporting on sex and gender	Patient sex is reported but was not required for analysis in our manuscript.
Reporting on race, ethnicity, or other socially relevant groupings	This information is not available and not required for analysis in our manuscript.
Population characteristics	This information is not available and not required for analysis in our manuscript.
Recruitment	Samples for this retrospective study were collected by medical oncologists at the Princess Alexandra Hospital (PAH). 2,678 patients with NSCLC were identified to have received platinum-based chemotherapy. TMAs were established based on curative treatment intent (fully resected, early-stage disease, who received adjuvant platinum-based chemotherapy). The Inclusion criteria were patients over 18 years of age, NSCLC cases treated only with adjuvant cisplatin/carboplatin in combination with vinorelbine, and tumour specimens were of adequate tissue availability for IHC staining.
Ethics oversight	This study has Metro South Human Research Ethics approval (LNR/2019/QMS/51117) and ratification by the Queensland University of Technology. This study has University of Queensland Human Research Ethics Approval (2021/HE001936).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	88
Data exclusions	After quality control, 61 patients tissue samples were included in analysis (48 paired samples and 13 unpaired samples).
Replication	N/A
Randomization	Tissues were randomized across the tissue microarrays
Blinding	N/A

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
☐	☒ Antibodies
☒	☐ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☒	☐ Animals and other organisms
☐	☒ Clinical data
☒	☐ Dual use research of concern
☒	☐ Plants

Methods

n/a	Involved in the study
☒	☐ ChIP-seq
☒	☐ Flow cytometry
☒	☐ MRI-based neuroimaging

Antibodies

Antibodies used	Provided in Table 2 in manuscript - Akoya Biosciences antibodies.
Validation	All antibodies used in this manuscript are validated by Akoya Biosciences.

Clinical data

Policy information about clinical studies

All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration	N/A
Study protocol	N/A
Data collection	Samples for this retrospective study were collected by medical oncologists at the Princess Alexandra Hospital (PAH). Using the lung cancer database, patients were filtered with the intent to collate a tumour-microarrays from archival lung cancer tissues that were collected at the time of diagnosis. 2,678 patients with NSCLC were identified to have received platinum-based chemotherapy. TMAs were established based on curative treatment intent (fully resected, early-stage disease, who received adjuvant platinum-based chemotherapy). The Inclusion criteria were patients over 18 years of age, NSCLC cases treated only with adjuvant cisplatin/ carboplatin in combination with vinorelbine, and tumour specimens were of adequate tissue availability for IHC staining.
Outcomes	Clinical metadata shown in Table 1.

Plants

Seed stocks	*Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.*
Novel plant genotypes	*Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor was applied.*
Authentication	*Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosiacism, off-target gene editing) were examined.*